Chinese cell and gene engineering company involved in cord-blood banking and cell-therapy services.
Chinese cell and gene engineering company involved in cord-blood banking and cell-therapy services.
Families pay an up-front processing fee, then yearly storage fees to keep cord blood frozen for possible future treatment, so income builds with the number of samples stored. Cell-therapy services extend the business beyond storage.
In one line: A China-based cord-blood bank/cell-therapy company.
Moat: narrow (regulatory licence, installed base). Cord-blood banking requires regional licences that limit new entrants.
Headquarters: Tianjin, China · Employees: 1,935
Size Vcanbio Cell & Gene Engineering (600645.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.11B, the 1956th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.09 on 18 Nov 2026.
Performance Over six months the shares fell 29.1%, against -13.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 6.3% over the last twelve months (peer median +8.6%); the operating margin is 11.7% (peer median 10.9%).
Valuation It trades at 40.7× forward earnings against a peer median of 16.7× (3rd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points above its cost of capital (6.8% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.38B | CN¥1.44B | CN¥1.57B | CN¥1.58B | CN¥1.55B |
| Revenue growth | — | -8% | -1% | +2% | — |
| Gross profit | CN¥1.03B | CN¥912M | CN¥984M | CN¥1.00B | CN¥959M |
| EBITDA | n/a | CN¥305M | CN¥317M | CN¥298M | CN¥296M |
| Net income | CN¥113M | CN¥114M | CN¥100M | CN¥106M | CN¥113M |
| Free cash flow | CN¥261M | CN¥276M | CN¥218M | CN¥210M | CN¥163M |
| Capital expenditure | CN¥41.4M | CN¥49.6M | CN¥67.3M | CN¥88.6M | CN¥99.2M |
| Total debt | CN¥64.7M | CN¥68.8M | CN¥112M | CN¥126M | CN¥130M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600645.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | -7.9% | 10th lowest of 21 |
| 6-month return | -29.1% | -13.9% | 6th lowest of 21 |
| Distance from 52-week high | -51.2% | -37.5% | 6th lowest of 21 |
| Revenue growth (TTM) | -6.3% | +8.6% | 2nd lowest of 21 |
| Operating margin | 11.7% | 10.9% | 9th highest of 21 |
| Forward P/E | 40.7× | 16.7× | 3rd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 8.9% | 7.7% | 7th least demanding of 13 |
| Growth delivered (Del g) | +1.9% | +11.8% | lowest of 12 |
| Hurdle (Req g minus delivered) | +7.0 pp | -11.6 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | +2.9 pp | -0.0 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vcanbio Cell & Gene Engineering 600645.SS | China | $1.11B | -29% | -6% | 12% | 40.7× | 8.9% | +1.9% |
| FESCO 600861.SS | China | $1.10B | -15% | +4% | 1% | 10.5× | n/a | n/a |
| Suzhou Novoprotein Scientific 688137.SS | China | $1.12B | +117% | +8% | -62% | n/a | n/a | n/a |
| Willdan WLDN | United States | $1.13B | -20% | +19% | 7% | 14.6× | 17.2% | +11.8% |
| China East Education 0667.HK | Hong Kong | $1.09B | -21% | +16% | 22% | 7.8× | -7.5% | +4.1% |
| Jadard Technology 688252.SS | China | $1.14B | -22% | +6% | 12% | 22.3× | 12.0% | +31.3% |
| Prosegur Cash CASH.MC | Spain | $1.07B | +10% | -2% | 11% | 9.6× | -12.1% | +5.7% |
| Resolute Holdings Management RHLD | United States | $1.16B | +34% | +10% | 12% | n/a | 16.6% | n/a |
| SBT Ultrasonic Technology 688392.SS | China | $1.06B | -36% | +42% | 17% | 49.3× | n/a | n/a |
| Nittetsu Mining 1515.T | Japan | $1.17B | -3% | +18% | 8% | n/a | n/a | n/a |
| Bajaj Mobility BMAG.SW | Switzerland | $1.05B | +40% | -47% | -44% | 8.9× | n/a | n/a |
| Shanxi Huaxiang 603112.SS | China | $1.19B | -33% | +9% | 11% | 11.6× | 0.9% | +16.2% |
| Siglent Technologies 688112.SS | China | $1.19B | -26% | +30% | 24% | 39.2× | 27.7% | +22.0% |
| Neurones NRO.PA | France | $1.03B | +3% | +7% | 9% | 16.9× | -7.9% | +10.3% |
| DOOSAN TESNA 131970.KS | South Korea | $1.03B | -62% | +5% | 10% | 43.1× | n/a | n/a |
| Service Stream SSM.AX | Australia | $1.03B | -9% | +1% | 3% | 16.7× | 13.9% | +24.0% |
| Naruida Technology 688522.SS | China | $1.01B | -32% | +20% | 14% | 19.6× | n/a | n/a |
| EMTEK (Shenzhen) 300938.SZ | China | $1,000M | -54% | +11% | 27% | 28.5× | n/a | n/a |
| Smartgroup SIQ.AX | Australia | $986M | -6% | +10% | 37% | 14.7× | -1.3% | +8.8% |
| GL events GLO.PA | France | $986M | -13% | +6% | 10% | 8.8× | 3.4% | +29.1% |
| Concord Biotech CONCORDBIO.NS | India | $1.26B | -2% | +4% | 28% | 33.9× | 44.4% | +11.6% |